Kezar Life Sciences, Inc. (NASDAQ:KZR) Given Consensus Recommendation of "Reduce" by Analysts

Key Points

• Analysts rate Kezar Life Sciences "Reduce": six analysts give a consensus "Reduce" (two sell, four hold) with an average 12‑month price target of $6.00.
• Recent results show large losses: Kezar reported Q1 EPS of ($1.99), missing estimates by $0.60 and analysts forecast about -2.24 EPS for the fiscal year, while the company has a market cap near $54.5 million.
• Institutional backing and clinical focus: Hedge funds own roughly 67.9% of the stock with several new positions added, and Kezar is a clinical‑stage biotech advancing KZR‑616, a selective immunoproteasome inhibitor in trials for autoimmune diseases.

Shares of Kezar Life Sciences, Inc. (NASDAQ:KZR - Get Free Report) have earned a consensus rating of "Reduce" from the six analysts that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $6.00.

Kezar Life Sciences Stock Performance

Shares of NASDAQ KZR opened at $7.39 on Tuesday. The company has a market cap of $54.46 million, a P/E ratio of -0.96 and a beta of 0.40. Kezar Life Sciences has a 52-week low of $3.53 and a 52-week high of $7.55. The firm's fifty day moving average is $7.06 and its two-hundred day moving average is $6.49.

Kezar Life Sciences (NASDAQ:KZR - Get Free Report) last released its quarterly earnings data on Friday, March 27th. The company reported ($1.99) EPS for the quarter, missing the consensus estimate of ($1.39) by ($0.60). As a group, analysts forecast that Kezar Life Sciences will post -2.24 EPS for the current fiscal year.

Hedge Funds Weigh In On Kezar Life Sciences

Institutional investors have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC bought a new stake in Kezar Life Sciences in the 4th quarter worth approximately $1,741,000. Affinity Asset Advisors LLC bought a new position in shares of Kezar Life Sciences during the 4th quarter valued at approximately $1,441,000. BML Capital Management LLC boosted its position in shares of Kezar Life Sciences by 13.5% during the 3rd quarter. BML Capital Management LLC now owns 720,787 shares of the company's stock valued at $2,811,000 after acquiring an additional 85,604 shares during the last quarter. Aldebaran Capital LLC purchased a new position in shares of Kezar Life Sciences in the fourth quarter valued at $507,000. Finally, Credit Industriel ET Commercial purchased a new position in shares of Kezar Life Sciences in the first quarter valued at $398,000. Hedge funds and other institutional investors own 67.90% of the company's stock.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapies that modulate the innate immune system. The company's research centers on selective inhibition of the immunoproteasome, a key protein complex involved in antigen processing and secretion of inflammatory cytokines. By targeting this pathway, Kezar aims to address unmet medical needs in autoimmune and inflammatory diseases with high specificity and a favorable safety profile.

The company's lead development candidate, KZR-616, is a selective immunoproteasome inhibitor being evaluated in multiple clinical trials for autoimmune conditions such as systemic lupus erythematosus, lupus nephritis, polymyositis and dermatomyositis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.